Company intelligence / Profile preview

Beta Therapeutics

Canberra, ACT, Australia

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Beta Therapeutics is developing small molecule inhibitors of heparanase for the treatment of inflammatory diseases including diabetic complications, retinopathy, cancer metastasis, syndromes, and kidney diseases. The company holds granted patents for heparanase inhibitors, but no clinical trial results are published as of October 2025.

Therapeutic areas: NephrologyImmunologyOphthalmologyEndocrinologyRare DiseasesOtherOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Beta Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta Therapeutics.

Explore the full profile